The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy…
The CAC 40 Index rose by ~12% this year and by nearly 20% from its lowest level in April when…
The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy…
The CAC 40 Index rose by ~12% this year and by nearly 20% from its lowest level in April when…